Jefferies Raises Price Target On Quest Diagnostics (DGX) to $66

Jefferies raised its price target on Hold-rated Quest Diagnostics (NYSE: DGX) from $61 to $66 following Q4 results.

The firm comments, "Good Q4 results along with prospects for improved volumes and expanded margins have given investors a shot of confidence in DGX and other healthcare service stocks. Looking ahead, though, we expect the momentum in DGX's stock price to taper a bit as we wait for (1) the announcement of a new CEO, (2) further evidence of improved utilization trends and (3) increased reimbursement visibility."

For an analyst ratings summary and ratings history on Quest Diagnostics click here. For more ratings news on Quest Diagnostics click here.

Shares of Quest Diagnostics closed at $60.55 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Suncrete Inc (RMIX) PT Lowered to $22 at Jefferies
• Stifel Downgrades Weave Communications Inc (WEAV) to Hold
• Raymond James Resumes Safehold (SAFE) at Market Perform